Ningzhi Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ningzhi Xu has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Hongxia Zhu
Cancer Institute & Cancer Hospital, Beijing, China
5 shared publications Mei Liu
Cancer Institute & Cancer Hospital, Beijing, China
5 shared publicationsChenfei Hu
Cancer Institute & Cancer Hospital, Beijing, China
3 shared publicationsHongxia Zhu
Laboratory of Cell and Molecular Biology and State Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 shared publicationsWei Zhang
3 shared publications- Yihua Wang
University of Southampton
3 shared publications
Latest Publications
- Open Access
- 16 October 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 278
Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma
Background: The overall survival of patients with esophageal squamous cell carcinoma (ESCC) remains poor. Prognostic predictions in ESCC are usually based on histological assessment of tumor invasion and lymph node metastasis, but a biomarker with better predictive accuracy could be more useful. Because overexpression of epidermal growth factor receptor (EGFR) has been associated with poor prognosis, this study investigated whether EGFR is an independent prognostic factor for overall survival and disease-free survival of ESCC patients. Methods: ESCC tissue specimens from 243 patients obtained during surgical resection between 1980 and 1997 were retrieved for immunohistochemical analysis of EGFR expression. Results: The data showed that EGFR protein was overexpressed in 187 of 243 (77%) ESCC tissues. Elevated expression was associated with higher pathologic tumor stages (P = 0.001), lymph node metastasis (P = 0.002), and higher Union for International Cancer Control (UICC) stage (P P P = 0.003) and overall survival (P = 0.001) of these patients. Subgroup analysis of patients with stage IIA (UICC 2002) showed that EGFR overexpression was associated with poorer disease-free survival (P = 0.007) and overall survival (P = 0.010) of the patients in univariate analyses. Conclusions: The current study demonstrated that EGFR overexpression was an independent prognostic factor for overall survival and disease-free survival of ESCC patients. However, targeting of EGFR activity using gefitinib or erlotinib could be useful for clinical treatment of ESCC patients.
- 16 October 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 278
Open AccessExpression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma
Background: The overall survival of patients with esophageal squamous cell carcinoma (ESCC) remains poor. Prognostic predictions in ESCC are usually based on histological assessment of tumor invasion and lymph node metastasis, but a biomarker with better predictive accuracy could be more useful. Because overexpression of epidermal growth factor receptor (EGFR) has been associated with poor prognosis, this study investigated whether EGFR is an independent prognostic factor for overall survival and disease-free survival of ESCC patients. Methods: ESCC tissue specimens from 243 patients obtained during surgical resection between 1980 and 1997 were retrieved for immunohistochemical analysis of EGFR expression. Results: The data showed that EGFR protein was overexpressed in 187 of 243 (77%) ESCC tissues. Elevated expression was associated with higher pathologic tumor stages (P = 0.001), lymph node metastasis (P = 0.002), and higher Union for International Cancer Control (UICC) stage (P P P = 0.003) and overall survival (P = 0.001) of these patients. Subgroup analysis of patients with stage IIA (UICC 2002) showed that EGFR overexpression was associated with poorer disease-free survival (P = 0.007) and overall survival (P = 0.010) of the patients in univariate analyses. Conclusions: The current study demonstrated that EGFR overexpression was an independent prognostic factor for overall survival and disease-free survival of ESCC patients. However, targeting of EGFR activity using gefitinib or erlotinib could be useful for clinical treatment of ESCC patients.
- 1 November 2012
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 5 (11_Supplem) , A19
Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer
Cervical cancer is one of the most common cancers in women worldwide. Advanced uterine cervical squamous cell carcinomasuterine (UCSCC) patients in FIGO stage IIb or IIIb treated with platinum based concomitant chemoradiotherapy. However, clinical outcomes vary significantly and are difficult to predict. Tumor intrinsic chemoradiotherapy sensitivity is one of the crucial reasons for concomitant chemoradiotherapy failure in UCSCC. In this study, we identified the relationship between miR-19a and sensitivity to concomitant chemoradiotherapy. The UCSCC patients in FIGO stage IIb or IIIb treated with platinum based concurrent chemoradiotherapy at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Patients with progressive disease during first line platinum based chemotherapy or those who suffered recurrent disease within 6 months of completing first line therapy were termed resistant. Patients without recurrence or with recurrences beyond 6 months were termed sensitive. We examined the expression level of miR-19a in 30 cervix biopsies samples, including 10 resistant and 20 sensitive samples. We found miR-19a was significantly up-regulated in resistant group compared with sensitive group (p Citation Format: Mei Liu, Lingying Wu, Ningzhi Xu, Jusheng An, Jinlong Hu, Manni Huang, Binbin Tu, Chenfei Hu, Zaozao Wang, Hongxia Zhu. miR-19a modulates chemoradiotherapy resistance in human cervical cancer. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr A19.
- 1 November 2012
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 5 (11_Supplem) , A19
Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer
Cervical cancer is one of the most common cancers in women worldwide. Advanced uterine cervical squamous cell carcinomasuterine (UCSCC) patients in FIGO stage IIb or IIIb treated with platinum based concomitant chemoradiotherapy. However, clinical outcomes vary significantly and are difficult to predict. Tumor intrinsic chemoradiotherapy sensitivity is one of the crucial reasons for concomitant chemoradiotherapy failure in UCSCC. In this study, we identified the relationship between miR-19a and sensitivity to concomitant chemoradiotherapy. The UCSCC patients in FIGO stage IIb or IIIb treated with platinum based concurrent chemoradiotherapy at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Patients with progressive disease during first line platinum based chemotherapy or those who suffered recurrent disease within 6 months of completing first line therapy were termed resistant. Patients without recurrence or with recurrences beyond 6 months were termed sensitive. We examined the expression level of miR-19a in 30 cervix biopsies samples, including 10 resistant and 20 sensitive samples. We found miR-19a was significantly up-regulated in resistant group compared with sensitive group (p Citation Format: Mei Liu, Lingying Wu, Ningzhi Xu, Jusheng An, Jinlong Hu, Manni Huang, Binbin Tu, Chenfei Hu, Zaozao Wang, Hongxia Zhu. miR-19a modulates chemoradiotherapy resistance in human cervical cancer. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr A19.
- Open Access
- 23 July 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (7) , e41862
Overexpression of the DEC1 Protein Induces Senescence In Vitro and Is Related to Better Survival in Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer-related death in China and has limited effective therapeutic options except for early surgery, since the underlying molecular mechanism driving its precursor lesions towards invasive ESCC is not fully understood. Cellular senescence is the state of the permanent growth arrest of a cell, and is considered as the initial barrier of tumor development. Human differentiated embryo chondrocyte expressed gene 1 (Dec1) is an important transcription factor that related to senescence. In this study, DEC1 immunohistochemical analysis was performed on tissue microarray blocks constructed from ESCC combined with adjacent precursor tissues of 241 patients. Compared with normal epithelia, DEC1 expression was significantly increased in intraepithelial neoplasia and DEC1 expression was significantly decreased in ESCC in comparison with intraepithelial neoplasia. In vitro, DEC1 overexpression induced cellular senescence, and it inhibited cell growth and colony formation in ESCC cell line EC9706. Fresh esophagectomy tissue sections from five ESCC patients were detected by immunohistochemistry of DEC1 and senescence-associated β-galactosidase (SA-β-Gal) activity, and strongly positive expression of DEC1 was correlated to more senescent cells in these fresh tissue sections. Kaplan – Meier method analysis of the 241 patients revealed that DEC1 expression levels were significantly correlated with the survival of ESCC patients after surgery. The expression levels of DEC1 were also correlated with age, tumor embolus, depth of invasion of ESCC, lymph metastasis status and pTNMs. These results suggest that DEC1 overexpression in precursor lesions of ESCC is a protective mechanism by inducing cellular senescence in ESCC initiation, and DEC1 may be a potential prognostic marker of ESCC.
- 23 July 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (7) , e41862
Open AccessOverexpression of the DEC1 Protein Induces Senescence In Vitro and Is Related to Better Survival in Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer-related death in China and has limited effective therapeutic options except for early surgery, since the underlying molecular mechanism driving its precursor lesions towards invasive ESCC is not fully understood. Cellular senescence is the state of the permanent growth arrest of a cell, and is considered as the initial barrier of tumor development. Human differentiated embryo chondrocyte expressed gene 1 (Dec1) is an important transcription factor that related to senescence. In this study, DEC1 immunohistochemical analysis was performed on tissue microarray blocks constructed from ESCC combined with adjacent precursor tissues of 241 patients. Compared with normal epithelia, DEC1 expression was significantly increased in intraepithelial neoplasia and DEC1 expression was significantly decreased in ESCC in comparison with intraepithelial neoplasia. In vitro, DEC1 overexpression induced cellular senescence, and it inhibited cell growth and colony formation in ESCC cell line EC9706. Fresh esophagectomy tissue sections from five ESCC patients were detected by immunohistochemistry of DEC1 and senescence-associated β-galactosidase (SA-β-Gal) activity, and strongly positive expression of DEC1 was correlated to more senescent cells in these fresh tissue sections. Kaplan – Meier method analysis of the 241 patients revealed that DEC1 expression levels were significantly correlated with the survival of ESCC patients after surgery. The expression levels of DEC1 were also correlated with age, tumor embolus, depth of invasion of ESCC, lymph metastasis status and pTNMs. These results suggest that DEC1 overexpression in precursor lesions of ESCC is a protective mechanism by inducing cellular senescence in ESCC initiation, and DEC1 may be a potential prognostic marker of ESCC.
- 1 April 2011
- Vol. 42 (2) , 91-4
[MiR-17-92 in cancer].
MicroRNAs (miRNAs) are a class of short regulatory non-coding RNAs (22-24 nt) widely expressed in living organisms. Shortly after their discovery, microRNAs are found to participate in the development of a variety of diseases. miR-17-92 and its paralog are one of them, recent studies have revealed their critical roles not only in the development of lung, heart, immune system but also in carcinogenesis. The present article mainly focuses on their different expression patterns and molecular mechanisms to elucidate their contribution to cancer development.
- 1 April 2011
- Vol. 42 (2) , 91-4
[MiR-17-92 in cancer].
MicroRNAs (miRNAs) are a class of short regulatory non-coding RNAs (22-24 nt) widely expressed in living organisms. Shortly after their discovery, microRNAs are found to participate in the development of a variety of diseases. miR-17-92 and its paralog are one of them, recent studies have revealed their critical roles not only in the development of lung, heart, immune system but also in carcinogenesis. The present article mainly focuses on their different expression patterns and molecular mechanisms to elucidate their contribution to cancer development.
- 22 September 2010
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 37 (5) , 1315-1321
Suppression of p21 by c-Myc through members of miR-17 family at the post-transcriptional level
The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy. Previous studies have shown that the expression of miR-17 family members has close relationship with the expression of c-Myc. Another study has reported p21 is a direct target of miR-17 family and their silencing of p21 contributes to tumor cell proliferation in part. Since c-Myc is a potent transcriptional repressor of p21, these findings suggest that c-Myc may negatively modulate p21 expression through an additional pathway except transcriptional suppression. In the study presented here, we compared p21 mRNA in the nucleus and cytoplasm of c-Myc stable transfectants with its control, which indicated further repression of p21 by c-Myc at the post-transcriptional level. Stem-loop and conventional real-time PCR showed elevated expression of some members in miR-17 family and their primary transcripts when c-Myc was stably overexpressed. To further investigate the relationship of c-Myc, miR-17 family and p21, we antagonized the expression of each miR-17 family member by transfection of their antisense oligonucleotides respectively in transfectants constitutively overexpressing c-Myc or not, and found that the restoration of p21 expression by treatment above was much stronger in the presence of c-Myc. These results suggest c-Myc could further repress p21 expression at the post-transcriptional level through some, but not all, members of miR-17 family.
- 22 September 2010
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 37 (5) , 1315-1321
Suppression of p21 by c-Myc through members of miR-17 family at the post-transcriptional level
The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy. Previous studies have shown that the expression of miR-17 family members has close relationship with the expression of c-Myc. Another study has reported p21 is a direct target of miR-17 family and their silencing of p21 contributes to tumor cell proliferation in part. Since c-Myc is a potent transcriptional repressor of p21, these findings suggest that c-Myc may negatively modulate p21 expression through an additional pathway except transcriptional suppression. In the study presented here, we compared p21 mRNA in the nucleus and cytoplasm of c-Myc stable transfectants with its control, which indicated further repression of p21 by c-Myc at the post-transcriptional level. Stem-loop and conventional real-time PCR showed elevated expression of some members in miR-17 family and their primary transcripts when c-Myc was stably overexpressed. To further investigate the relationship of c-Myc, miR-17 family and p21, we antagonized the expression of each miR-17 family member by transfection of their antisense oligonucleotides respectively in transfectants constitutively overexpressing c-Myc or not, and found that the restoration of p21 expression by treatment above was much stronger in the presence of c-Myc. These results suggest c-Myc could further repress p21 expression at the post-transcriptional level through some, but not all, members of miR-17 family.
- 19 April 2010
- Published by Wiley in Cancer Science
- Vol. 101 (5) , 1156-1162
Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2–β‐catenin/TCF4‐survivin pathway in ErbB2‐overexpressed breast cancer cells
Overexpression of ErbB2 is associated with poor prognosis in breast cancer. Targeting of ErbB2 is a very common therapeutic strategy in ErbB2‐overexpressed breast cancer. Herceptin is the first approved and most widely used agent for ErbB2‐targeting therapy in breast cancer. Even though the clinical application has been performed for more than 10 years, the exact mechanism underlying how Herceptin exhibits its effects has not been fully elucidated. In this study, we found that Herceptin could inhibit the expression of survivin in ErbB2‐overexpressed cell lines. Overexpression of survivin could abrogate the inhibition of cell growth induced by Herceptin. Herceptin could reduce survivin expression at the transcriptional level. The β‐catenin/T‐cell factor (TCF) pathway played a very crucial role in this cascade. We found that Herceptin could reduce tyrosine phosphorylation levels of ErbB2 and β‐catenin. Herceptin treatment induced degradation of β‐catenin protein, resulting in reduced binding affinity of β‐catenin/TCF4 to the promoter region of survivin. When we cross‐mutated the TCF4 binding sites in the promoter region of survivin, the reduction of survivin promoter activity almost diminished. Taken together, we showed that Herceptin could inhibit survivin expression through the ErbB2–β‐catenin/TCF4‐survivin pathway in ErbB2‐overexpressed breast cancer cells. This indicates that there may be a new cascade axis from ErbB2 to survivin.(Cancer Sci 2010; 101: 1156–1162)
- 19 April 2010
- Published by Wiley in Cancer Science
- Vol. 101 (5) , 1156-1162
Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2–β‐catenin/TCF4‐survivin pathway in ErbB2‐overexpressed breast cancer cells
Overexpression of ErbB2 is associated with poor prognosis in breast cancer. Targeting of ErbB2 is a very common therapeutic strategy in ErbB2‐overexpressed breast cancer. Herceptin is the first approved and most widely used agent for ErbB2‐targeting therapy in breast cancer. Even though the clinical application has been performed for more than 10 years, the exact mechanism underlying how Herceptin exhibits its effects has not been fully elucidated. In this study, we found that Herceptin could inhibit the expression of survivin in ErbB2‐overexpressed cell lines. Overexpression of survivin could abrogate the inhibition of cell growth induced by Herceptin. Herceptin could reduce survivin expression at the transcriptional level. The β‐catenin/T‐cell factor (TCF) pathway played a very crucial role in this cascade. We found that Herceptin could reduce tyrosine phosphorylation levels of ErbB2 and β‐catenin. Herceptin treatment induced degradation of β‐catenin protein, resulting in reduced binding affinity of β‐catenin/TCF4 to the promoter region of survivin. When we cross‐mutated the TCF4 binding sites in the promoter region of survivin, the reduction of survivin promoter activity almost diminished. Taken together, we showed that Herceptin could inhibit survivin expression through the ErbB2–β‐catenin/TCF4‐survivin pathway in ErbB2‐overexpressed breast cancer cells. This indicates that there may be a new cascade axis from ErbB2 to survivin.(Cancer Sci 2010; 101: 1156–1162)
- 10 April 2009
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 390 (5-6) , 463-469
Krüppel-like factor 4 represses transcription of the survivin gene in esophageal cancer cell lines
Aberrant expression of survivin has been shown to be regulated at the transcription level in cancer cells. In this study, we demonstrate that there are six putative binding sites of Krüppel-like factor 4 (KLF4) within the 2000-bp region upstream of the transcription start site of the human survivin gene. Luciferase reporter gene assays revealed that survivin promoter activity is repressed upon overexpression of KLF4 in EC9706 cells. A chromatin immunoprecipitation assay indicated that KLF4 indeed binds the survivin promoter in vivo. It specifically binds the site located at position -40 among the six binding sites as determined by electrophoretic mobility shift assay. Ectopic expression of KLF4 decreases the mRNA and protein levels of survivin. Furthermore, overexpression of survivin partially reverses KLF4-induced cell apoptosis. These results indicate that KLF4 is a transcriptional repressor of the human survivin gene in esophageal squamous cancer cells.
- 10 April 2009
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 390 (5-6) , 463-469
Krüppel-like factor 4 represses transcription of the survivin gene in esophageal cancer cell lines
Aberrant expression of survivin has been shown to be regulated at the transcription level in cancer cells. In this study, we demonstrate that there are six putative binding sites of Krüppel-like factor 4 (KLF4) within the 2000-bp region upstream of the transcription start site of the human survivin gene. Luciferase reporter gene assays revealed that survivin promoter activity is repressed upon overexpression of KLF4 in EC9706 cells. A chromatin immunoprecipitation assay indicated that KLF4 indeed binds the survivin promoter in vivo. It specifically binds the site located at position -40 among the six binding sites as determined by electrophoretic mobility shift assay. Ectopic expression of KLF4 decreases the mRNA and protein levels of survivin. Furthermore, overexpression of survivin partially reverses KLF4-induced cell apoptosis. These results indicate that KLF4 is a transcriptional repressor of the human survivin gene in esophageal squamous cancer cells.
- 1 March 2009
- Vol. 31 (3) , 174-7
[Effects of survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP].
To explore a new approach in gene therapy of ovarian cancer, we used RNAi to inhibit survivin gene expression, and explore the effect of survivin and neu RNAi on growth, apoptosis and chemosensitivity of ovarian cancer cell line SKOV3/DDP cells. Expression vector of survivin gene-targeting siRNA was constructed using pSilencer 1.0-U6 vector containing U6 promotor (pSilencer-survivin) and transfected into SKOV3/DDP cells by lipofectamine. The untransfected group and pSilencer-control group were used as control. The expressions of survivin mRNA and protein were identified by RT-PCR and Western blot assay. The proliferation of SKOV3/DDP cells was determined by MTT assay. The apoptosis rate and cell cycle distribution were analyzed by flow cytometry. Cisplatin (DDP) resistance experiment was performed in SKOV3/DDP cells with RNAi. Survivin RNAi plasmid knocked-down survivin expression in SKOV3/DDP cells obviously, arrested the cells at G(1)/G(0) phase, inhibited the cell proliferation and promoted cell apoptosis. The IC(50) of DDP to SKOV3/DDP cells transfected with survivin siRNA was dropped. Survivin RNAi can partly suppress the expression of survivin in SKOV3/DDP cells, inhibit the cell proliferation and promote cell apoptosis. Survivin RNAi can enhance the cell sensitivity to apoptosis induced by cisplatin, which implies that survivin RNAi may partly reverse the drug resistance of ovarian cancer. RNAi could be a new approach for gene therapy of cancer.
- 1 March 2009
- Vol. 31 (3) , 174-7
[Effects of survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP].
To explore a new approach in gene therapy of ovarian cancer, we used RNAi to inhibit survivin gene expression, and explore the effect of survivin and neu RNAi on growth, apoptosis and chemosensitivity of ovarian cancer cell line SKOV3/DDP cells. Expression vector of survivin gene-targeting siRNA was constructed using pSilencer 1.0-U6 vector containing U6 promotor (pSilencer-survivin) and transfected into SKOV3/DDP cells by lipofectamine. The untransfected group and pSilencer-control group were used as control. The expressions of survivin mRNA and protein were identified by RT-PCR and Western blot assay. The proliferation of SKOV3/DDP cells was determined by MTT assay. The apoptosis rate and cell cycle distribution were analyzed by flow cytometry. Cisplatin (DDP) resistance experiment was performed in SKOV3/DDP cells with RNAi. Survivin RNAi plasmid knocked-down survivin expression in SKOV3/DDP cells obviously, arrested the cells at G(1)/G(0) phase, inhibited the cell proliferation and promoted cell apoptosis. The IC(50) of DDP to SKOV3/DDP cells transfected with survivin siRNA was dropped. Survivin RNAi can partly suppress the expression of survivin in SKOV3/DDP cells, inhibit the cell proliferation and promote cell apoptosis. Survivin RNAi can enhance the cell sensitivity to apoptosis induced by cisplatin, which implies that survivin RNAi may partly reverse the drug resistance of ovarian cancer. RNAi could be a new approach for gene therapy of cancer.
- 20 November 2007
- Vol. 87 (43) , 3069-73
[Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer].
To establish a model to predict the clinical response of Gefitinib in non-small cell lung cancer (NSCLC). The clinical outcomes of 262 consecutive advanced NSCLC patients to oral treatment of gefitinib 250 mg daily in the past 4 years were reviewed. DNA sequencing was used to detect the mutations in the exons 18, 19, 20, and 21 of the epidermal growth factor receptor (EGFR) tyrosine kinase domain in 55 patients who had enough tumor tissues. The response rate and disease control rate of gefitinib in the advanced NSCLC patients were 30.1% and 78.6% respectively. The median progression free survival and median overall survival were 6.0 and 16.0 months respectively, while the 1, 2 and 3-year survival rates of the NSCLC patients were 60.8%, 35.6%, and 18.3% respectively. The clinical response rate of the patients with EGFR mutation was 50.0%, significantly higher than that of those patients without mutation (16.1%; P = 0.009). In the majority of patients Gefitinib was well tolerated, and the common adverse effects were skin rash and diarrhea. Based on the results of our patients, we try to establish a model which may predict the response of patients by logistic multivariate regression analysis. Patients being female aged under 65, with adenocarcinoma, not smoking, taxone-unresistant and with EGFR mutation were more sensitive to gifitinib. However, COX multivariate regression analysis showed that only the age, histology, smoke status and EGFR mutation were valuable in selection of sensitive patients. So, we set up the cut-off value at 2 in the model based on these 4 factors. The response rate of the patients with 2 or more scores was 34.2%, significantly higher than that of the patients with the scores < 2 (9.3%, P = 0.001). The sensitivity would be doubled when the score increases by one point. A simple clinical model based on the patients' age, histology, smoking status and EGFR mutation has been established and is useful to determine the efficacy of gifitinib in NSCLC patients.
- 20 November 2007
- Vol. 87 (43) , 3069-73
[Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer].
To establish a model to predict the clinical response of Gefitinib in non-small cell lung cancer (NSCLC). The clinical outcomes of 262 consecutive advanced NSCLC patients to oral treatment of gefitinib 250 mg daily in the past 4 years were reviewed. DNA sequencing was used to detect the mutations in the exons 18, 19, 20, and 21 of the epidermal growth factor receptor (EGFR) tyrosine kinase domain in 55 patients who had enough tumor tissues. The response rate and disease control rate of gefitinib in the advanced NSCLC patients were 30.1% and 78.6% respectively. The median progression free survival and median overall survival were 6.0 and 16.0 months respectively, while the 1, 2 and 3-year survival rates of the NSCLC patients were 60.8%, 35.6%, and 18.3% respectively. The clinical response rate of the patients with EGFR mutation was 50.0%, significantly higher than that of those patients without mutation (16.1%; P = 0.009). In the majority of patients Gefitinib was well tolerated, and the common adverse effects were skin rash and diarrhea. Based on the results of our patients, we try to establish a model which may predict the response of patients by logistic multivariate regression analysis. Patients being female aged under 65, with adenocarcinoma, not smoking, taxone-unresistant and with EGFR mutation were more sensitive to gifitinib. However, COX multivariate regression analysis showed that only the age, histology, smoke status and EGFR mutation were valuable in selection of sensitive patients. So, we set up the cut-off value at 2 in the model based on these 4 factors. The response rate of the patients with 2 or more scores was 34.2%, significantly higher than that of the patients with the scores < 2 (9.3%, P = 0.001). The sensitivity would be doubled when the score increases by one point. A simple clinical model based on the patients' age, histology, smoking status and EGFR mutation has been established and is useful to determine the efficacy of gifitinib in NSCLC patients.
- 1 August 2004
- Vol. 26 (8) , 458-60
[Suppression of c-myc expression by interference RNA in HepG2 hepatocellular carcinoma cells].
To study the inhibitory effect of RNA interference (RNAi) on c-myc expression in hepatocellular carcinoma cell line, HepG2. Expression vector of c-myc gene-targeting small interference RNA (siRNA) was constructed (psilencer-c-myc) and transfected into HepG2 cells by lipofectamine, and the unloaded vector was used as control (mock). The expression of c-myc mRNA and protein was identified by quantitive PCR and Western blot. Apoptosis of the transfected cells was examined by flow cytometry and immunofluorescent microscopy. After HepG2 cells were transfected with psilencer-c-myc, the expression of c-myc mRNA and protein was suppressed with an inhibition rate of 67% compared with the mock-transfected cells. Apoptosis was identified in the transfected HepG2 cells. The expression of c-myc at transcriptional and translational levels in HepG2 cells transfected with siRNA is markedly inhibited, which may be associated with the induction of apoptosis.
- 1 August 2004
- Vol. 26 (8) , 458-60
[Suppression of c-myc expression by interference RNA in HepG2 hepatocellular carcinoma cells].
To study the inhibitory effect of RNA interference (RNAi) on c-myc expression in hepatocellular carcinoma cell line, HepG2. Expression vector of c-myc gene-targeting small interference RNA (siRNA) was constructed (psilencer-c-myc) and transfected into HepG2 cells by lipofectamine, and the unloaded vector was used as control (mock). The expression of c-myc mRNA and protein was identified by quantitive PCR and Western blot. Apoptosis of the transfected cells was examined by flow cytometry and immunofluorescent microscopy. After HepG2 cells were transfected with psilencer-c-myc, the expression of c-myc mRNA and protein was suppressed with an inhibition rate of 67% compared with the mock-transfected cells. Apoptosis was identified in the transfected HepG2 cells. The expression of c-myc at transcriptional and translational levels in HepG2 cells transfected with siRNA is markedly inhibited, which may be associated with the induction of apoptosis.